BR112022005999A2 - Métodos de tratamento de condições relacionadas ao receptor s1p1 - Google Patents

Métodos de tratamento de condições relacionadas ao receptor s1p1

Info

Publication number
BR112022005999A2
BR112022005999A2 BR112022005999A BR112022005999A BR112022005999A2 BR 112022005999 A2 BR112022005999 A2 BR 112022005999A2 BR 112022005999 A BR112022005999 A BR 112022005999A BR 112022005999 A BR112022005999 A BR 112022005999A BR 112022005999 A2 BR112022005999 A2 BR 112022005999A2
Authority
BR
Brazil
Prior art keywords
methods
receiver
treatment
conditions related
acid
Prior art date
Application number
BR112022005999A
Other languages
English (en)
Inventor
Curtis Nguyen-Cleary Thai
Marie Acevedo Lisette
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of BR112022005999A2 publication Critical patent/BR112022005999A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A presente invenção refere-se a métodos de tratamento da Doença de Crohn compreendendo prescrever e/ou administrar a um indivíduo que dele necessite uma dose padrão de ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benzilóxi)-1,2,3,4-tetra-hidrociclopenta[b]indol-3-il)acético (Composto 1), ou um sal, hidrato ou solvato farmaceuticamente aceitável do mesmo.
BR112022005999A 2019-10-01 2020-09-30 Métodos de tratamento de condições relacionadas ao receptor s1p1 BR112022005999A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962909113P 2019-10-01 2019-10-01
PCT/US2020/053642 WO2021067506A1 (en) 2019-10-01 2020-09-30 Methods of treating conditions related to the s1p1 receptor

Publications (1)

Publication Number Publication Date
BR112022005999A2 true BR112022005999A2 (pt) 2022-07-12

Family

ID=75337529

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005999A BR112022005999A2 (pt) 2019-10-01 2020-09-30 Métodos de tratamento de condições relacionadas ao receptor s1p1

Country Status (12)

Country Link
US (1) US20220347158A1 (pt)
EP (1) EP4037678A4 (pt)
JP (1) JP2022550458A (pt)
KR (1) KR20220074913A (pt)
CN (1) CN115038438A (pt)
AU (1) AU2020360413A1 (pt)
BR (1) BR112022005999A2 (pt)
CA (1) CA3156182A1 (pt)
IL (1) IL291654A (pt)
MX (1) MX2022003982A (pt)
TW (1) TW202114656A (pt)
WO (1) WO2021067506A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023135506A1 (en) 2022-01-13 2023-07-20 Arena Pharmaceuticals, Inc. Etrasimod for use in treating s1p1 receptor-associated disorders in combination with hormone treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE030424T2 (en) * 2008-07-23 2017-05-29 Arena Pharm Inc Substituted 1,2,3,4-tetrahydrocyclopenta [b] indol-3-ylacetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
CN103221391B (zh) * 2010-01-27 2018-07-06 艾尼纳制药公司 (R)-2-(7-(4-环戊基-3-(三氟甲基)苄基氧基)-1,2,3,4-四氢环戊二烯并[b]吲哚-3-基)乙酸及其盐的制备方法
CN107405332A (zh) * 2015-01-06 2017-11-28 艾尼纳制药公司 治疗与s1p1受体有关的病症的方法
MA47503A (fr) * 2017-02-16 2021-04-21 Arena Pharm Inc Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales

Also Published As

Publication number Publication date
TW202114656A (zh) 2021-04-16
JP2022550458A (ja) 2022-12-01
WO2021067506A1 (en) 2021-04-08
EP4037678A4 (en) 2023-11-29
EP4037678A1 (en) 2022-08-10
CA3156182A1 (en) 2021-04-08
MX2022003982A (es) 2022-07-12
AU2020360413A8 (en) 2022-04-21
KR20220074913A (ko) 2022-06-03
US20220347158A1 (en) 2022-11-03
CN115038438A (zh) 2022-09-09
IL291654A (en) 2022-05-01
AU2020360413A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
BR112022012846A2 (pt) Métodos de tratamento de condições relacionadas ao receptor s1p1
Öbrink et al. Post-operative nausea and vomiting: update on predicting the probability and ways to minimize its occurrence, with focus on ambulatory surgery
Leppänen et al. Clinical efficacy and safety of dexmedetomidine and buprenorphine, butorphanol or diazepam for canine hip radiography
MX2020013157A (es) Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.
MX2021006575A (es) Composiciones y metodos para el tratamiento de trastornos del higado.
WO2005046318A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
MX2019012884A (es) Terapia de combinacion.
Taylor et al. A multicentre, prospective, randomised, blinded clinical trial to compare some perioperative effects of buprenorphine or butorphanol premedication before equine elective general anaesthesia and surgery
MX2017003066A (es) Composiciones farmaceuticas que comprenden un compuesto de dextrometorfano y quinidina para el tratamiento de agitacion en demencia.
EA202191079A1 (ru) Способы лечения синдрома ретта с применением фенфлурамина
Ko et al. Evaluation of dexmedetomidine and ketamine in combination with various opioids as injectable anesthetic combinations for castration in cats
EA201891931A1 (ru) Новые ингибиторы фосфатидилинозитол-3-киназы гамма
Maud et al. Evidence for the use of isoflurane as a replacement for chloral hydrate anesthesia in experimental stroke: an ethical issue
MX2021008263A (es) Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.
BR112022007348A2 (pt) Métodos para tratar condições relacionadas ao receptor s1p1
BR112022005999A2 (pt) Métodos de tratamento de condições relacionadas ao receptor s1p1
CY1124236T1 (el) Διαλυμα εγχυσης λεβοντοπα
CA3010609A1 (en) Treatments and prevention of opioid neonatal abstinence syndrome
PL1610787T3 (pl) Synergiczna kombinacja zawierająca roflumilast i środek antycholinergiczny wybrany z soli tiotropium do leczenia chorób układu oddechowego
McFadzean et al. Perioperative pain management in horses
BR112019018185A2 (pt) composição para tratar uma doença de articulação humana, e, kit.
Alnimer et al. Primary idiopathic osteoarthropathy: could it be related to alcoholism?
MX2021001228A (es) Composicion para uso en la prevencion y/o tratamiento de la mucosa genitourinaria.
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
MX2022000297A (es) Formulacion de naltrexona.

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: ARENA PHARMACEUTICALS, INC. (US)

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]